TyraTech, Inc. Head-Lice Preventative Shampoo Coming to US Market (0029Y)
January 20 2014 - 1:00AM
UK Regulatory
TIDMTYR TIDMTYRU
RNS Number : 0029Y
TyraTech, Inc.
20 January 2014
20 January 2014
TyraTech, Inc.
("TyraTech" or the "Company")
Vamousse(TM) head lice preventative shampoo coming to market in
the USA
TyraTech, Inc. (AIM: TYR and TYRU) a life sciences company
focusing on nature-derived insect and parasite control products, is
pleased to announce its pioneering, over-the-counter head lice
preventative shampoo product, Vamousse(TM), is now listed with the
USA Food and Drug Administration ("FDA") and will be available for
sale in the USA from the end of Q1 2014. The Vamousse Preventative
Shampoo is a new product in the Vamousse range of head lice
products and complements the Vamousse Treatment.
The Vamousse(TM) preventative shampoo product is targeting a new
market, the prevention rather than the treatment of head lice
infestation. The product provides a unique solution to help prevent
head lice infestation. The shampoo can be used on a regular basis
to prevent head lice infestation in children in at-risk situations
(sleep-overs, camps, sports, events with friends, etc.) as well as
to protect the whole family when an infestation occurs in one of
its members. TyraTech believes that this product has the potential
to give it access to a new market segment for prevention and for
routine use of the product whereas existing head lice treatments
are only used on an emergency basis and only for individuals that
are already infested.
In addition, the new Vamousse(TM) preventative shampoo product
will enable TyraTech to further expand its market penetration by
offering a larger range of products for both head lice treatment
and prevention. TytraTech believes that the Vamousse Preventative
Shampoo will be distributed initially on-line and in
brick-and-mortar distributors in the USA.
Bruno Jactel, Chief Executive Officer, said: "We have been
working diligently to accelerate the development of this
breakthrough preventative head lice shampoo targeting a new and
potentially significant market. We are delighted to announce that
we are now FDA listed and ready to launch in the US market. This
product will be available soon in traditional retail and
internet-based distributors. We feel confident that TyraTech's
unique and complete product offering will help us to establish a
significant market presence. TyraTech believes it is well
positioned to meet market expectations for 2014 revenues."
Further information on Vamousse(TM) is available on the
Company's website at:
http://www.tyratech.com/content/company-products/head-lice.asp
For further information please contact:
TyraTech Inc.
Alan Reade, Non-Executive Chairman Tel: +44 7841 978709
Bruno Jactel, Chief Executive Officer Tel: +1 919 415 4340
SPARK Advisory Partners Limited, Nominated Adviser
Matt Davis / Mark Brady Tel: +44 20 3368 3551
Allenby Capital Limited , Joint Broker
Chris Crawford Tel: +44 20 3328 5656
Whitman Howard Limited, Joint Broker
Ranald Mc-Gregor Smith / Niall Devins Tel: +44 20 7087 4555
Walbrook, Financial PR and IR
Bob Huxford /Guy McDougall (Public Relations) Tel: +44 20 7933 8792
Paul Cornelius (Investor Relations) Tel: +44 20 7933 8794
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFSTLIIALIS
Tyratech (LSE:TYR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tyratech (LSE:TYR)
Historical Stock Chart
From Jul 2023 to Jul 2024